Effect of taurine in reducing acute kidney injury

Upregulating Heme Oxygenase-1 by Taurine to reduce Acute Kidney Injury in cardiac surgery: a phase II randomised controlled trial (the HOT-AKI trial) - the HOT-AKI trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500102159

Enrollment

Unknown

Registered

2025-05-09

Start date

2025-10-01

Completion date

Unknown

Last updated

2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute kidney injury

Interventions

intervention group:Participants in this group will receive 4g of taurine (1g/capsule x 4 in one sitting) orally the day before surgery, and 4g daily orally for two days post-surgery (or via nasogastri

control group:Participants in this group will receive an indistinguishable placebo (1g/capsule x 4 in one sitting) [Colorcon called StarCap - a mixture of pregelatinized maize starch and maize starch]

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria • Elective cardiac surgery requiring cardiopulmonary bypass (primary and redo isolated coronary artery bypass grafting, aortic valve repair or replacement, mitral valve repair or replacement, combined coronary artery bypass with valve procedures, repair of septal defects, repair of congenital heart defects, and aortic aneurysm repair surgery). • Aged >= 18 years

Exclusion criteria

Exclusion criteria: Exclusion criteria • Emergency cardiac surgery when administration of taurine at least 12 hours before initiation of surgery is not possible; • Treating clinician believes that trial participation is not in the best interests of the patient; • Patients with significant renal impairment (eGFR <30ml/min) will be excluded due to the body’s excretion of excess taurine through the kidneys. • Patients undergoing minimally invasive cardiac surgery and endovascular aortic surgery (transcatheter aortic valve implantation) not requiring cardiopulmonary bypass will be excluded to enrich the trial population at high risk of AKI.

Design outcomes

Primary

Measure	Time frame
urinary concentrations of tissue inhibitor of metalloproteinase (TIMP-2);insulin-like growth factor-binding protein (IGFBP7);KDIGO;	—

Secondary

Measure	Time frame
plasma HO-1;urinary HO-1;urinary concentrations of neutrophil gelatinase-associated lipocalin (NGAL);	—

Countries

China

Contacts

Public ContactAnna LEE

Department of Anesthesia and Intensive Care, The Chinese University of Hong Kong

annalee@cuhk.edu.hk+852 3505 2735

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026